IShares Biotechnology Financial Statements From 2010 to 2024
| IBB Etf | USD 132.96 2.31 1.77% |
Check IShares Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among IShares main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . IShares financial statements analysis is a perfect complement when working with IShares Biotechnology Valuation or Volatility modules.
IShares |
iShares Biotechnology ETF ETF Price To Sales Analysis
IShares Biotechnology's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current IShares Biotechnology Price To Sales | 4.94 X |
Most of IShares Biotechnology's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, iShares Biotechnology ETF is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
IShares Biotechnology Price To Sales Component Assessment
Based on the latest financial disclosure, iShares Biotechnology ETF has a Price To Sales of 4.94 times. This is much higher than that of the iShares family and 86.77% higher than that of the Health category. The price to sales for all United States etfs is notably lower than that of the firm.
iShares Biotechnology ETF Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining IShares Biotechnology's current stock value. Our valuation model uses many indicators to compare IShares Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IShares Biotechnology competition to find correlations between indicators driving IShares Biotechnology's intrinsic value. More Info.iShares Biotechnology ETF is considered the top ETF in price to earning as compared to similar ETFs. It is considered the top ETF in price to book as compared to similar ETFs fabricating about 1.07 of Price To Book per Price To Earning. Comparative valuation analysis is a catch-all model that can be used if you cannot value IShares Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for IShares Biotechnology's Etf. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the IShares Biotechnology's earnings, one of the primary drivers of an investment's value.About IShares Biotechnology Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include IShares Biotechnology income statement, its balance sheet, and the statement of cash flows. IShares Biotechnology investors use historical funamental indicators, such as IShares Biotechnology's revenue or net income, to determine how well the company is positioned to perform in the future. Although IShares Biotechnology investors may use each financial statement separately, they are all related. The changes in IShares Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on IShares Biotechnology's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on IShares Biotechnology Financial Statements. Understanding these patterns can help to make the right decision on long term investment in IShares Biotechnology. Please read more on our technical analysis and fundamental analysis pages.
The fund generally will invest at least 80 percent of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Nasdaq Biotechnology is traded on NASDAQ Exchange in the United States.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of IShares Biotechnology Correlation against competitors. Note that the iShares Biotechnology ETF information on this page should be used as a complementary analysis to other IShares Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
The market value of iShares Biotechnology ETF is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is IShares Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Biotechnology's market value can be influenced by many factors that don't directly affect IShares Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.